John Janco's questions to CorMedix Inc (CRMD) leadership • Q2 2024
Question
John Janco, on for Serge Belanger, asked about the trial and adoption process for DefenCath, seeking to understand the differences between inpatient and outpatient segments. He also inquired if the TDAPA reimbursement process is operating seamlessly and if most operators are familiar with it.
Answer
CEO Joseph Todisco explained that while TDAPA systems are in place, some smaller operators still require education on the process. EVP & Chief Clinical Strategy and Operations Officer Elizabeth Masson-Hurlburt detailed the adoption differences, noting the inpatient process is longer due to P&T committees and EMR integration, whereas outpatient adoption can be faster but still requires significant operational rollout, training, and protocol development.